Allergan Inc (AGN.N)

AGN.N on New York Stock Exchange

91.27USD
1 Aug 2013
Price Change (% chg)

$0.15 (+0.16%)
Prev Close
$91.12
Open
$92.23
Day's High
$92.92
Day's Low
$91.04
Volume
583,387
Avg. Vol
650,189
52-wk High
$116.44
52-wk Low
$81.34

AGN.N

Chart for AGN.N

About

Allergan, Inc., is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company operates in two segments: specialty pharmaceuticals and medical devices. On June 17, 2011, it acquired Alacer Biomedical, Inc. (Alacer). On... (more)

Overall

Beta: 0.83
Market Cap (Mil.): $27,052.47
Shares Outstanding (Mil.): 296.40
Dividend: 0.05
Yield (%): 0.22

Financials

  AGN.N Industry Sector
P/E (TTM): 23.14 37.93 37.76
EPS (TTM): 3.94 -- --
ROI: 14.78 19.48 18.76
ROE: 21.41 20.17 19.59
Search Stocks

Elan seeks bids from Allergan, Forest: sources

NEW YORK - Irish drugmaker Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc , several people familiar with the matter said on Friday.

12 Jul 2013

UPDATE 1-Elan seeks bids from Allergan, Forest -sources

NEW YORK, July 12 - Irish drugmaker Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc, several people familiar with the matter said on Friday.

12 Jul 2013

First-round bids for Elan due next week -sources

NEW YORK, July 12 - Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc, several people familiar with the matter said on Friday.

12 Jul 2013

DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan

NEW YORK, June 27 - The game may not yet be over for U.S investment firm Royalty Pharma in its months-long pursuit of Elan Corp.

27 Jun 2013

FDA draft guidance on generic eye drug push Allergen shares lower

WASHINGTON - Shares of Allergan Inc fell 12 percent on Monday after U.S. regulators issued draft guidance that would enable generic versions of the company's dry eye drug Restasis to come to market more quickly.

24 Jun 2013

Allergan delays drug that would rival Regeneron's Eylea

- Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

01 May 2013

UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea

May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

01 May 2013

Allergan delays eye drug, shares fall

- Allergan Inc , maker of the Botox anti-wrinkle treatment, said it will delay late-stage trials of its highly anticipated eye drug Darpin, sending its shares down 14 percent.

01 May 2013

BRIEF-Regeneron Pharma shares resume trading, up 16 percent

NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval

01 May 2013

BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3

NEW YORK, May 1 - Allergan Inc : * Resumes trading down 11.5 percent after company says phase 2 Darpin eye drug data does not support directly moving to phase 3

01 May 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks